An FDA advisory panel endorsed Grail’s multi-cancer early detection blood test, Galleri, concluding that benefits outweigh risks for adults meeting the proposed indication. The panel voted 10–0 on safety and 6–4 on effectiveness, reflecting persistent debate over clinical value despite strong specificity signals. In the Nature Medicine evidence package of more than 35,000 participants, Galleri detected signs of cancer in 287 people, with about 60% later diagnosed. The test also predicted likely tissue of origin in roughly 91% of cases. A negative result does not rule out cancer, and the FDA is not required to follow the panel’s recommendation. The decision keeps pressure on the early-detection field to demonstrate that earlier intervention translates into fewer advanced cancers and cancer deaths, not just higher detection rates.